摘要
目的探索切除修复交叉互补基因1(ERCC1)、胸苷酸合成酶(TS)、β-微管蛋白和尿苷二磷酸葡萄糖醛酸转移酶1A1(UGT1A1)检测的对于胃癌化疗敏感性的关系。方法将120例进展期或术后复发的胃癌患者随机分为2组,对照组采用FOLFOX4方案、FOLFIRI方案或者DCF方案,试验组进行基因mRNA表达水平检测,并根据检测结果针对性地选择上述3种方案。观察2组患者的近期疗效和生活质量。结果 2组患者均接受2个周期以上的化疗。试验组有效率及生活质量改善率均显著高于对照组(P<0.05)。结论 ERCC1、TS、β-微管蛋白和UGT1A1的表达水平对于晚期胃癌化疗敏感性的预测有着重要的意义,值得临床进一步研究。
Objective To investigate the relationship between the mRNA expression of ER- CC1, TS, β tubulin, UGT1A1 and the sensitivity of chemotherapy in gastric cancer patients. Methods A total of 120 gastric cancer patients were randomly divided into two groups. The control group received FOLFOX4, FOLFIRI or DCF. The mRNA expressions of the patients of experi- ment group were detected at first. Then the above chemotherapy regimen was administered accord- ing to the detection results. The response rate and quality of life of the two groups was observed re- spectively. Results The response rate and the improvement rate of quality of life in the experiment group were higher than those in the control group （P 〈 0.05）. Conclusion The mRNA expression of ERCC1, TS, β- tubulin, UGT1A1 is sensitive in the treatment of gastric cancer patients.
出处
《实用临床医药杂志》
CAS
2012年第19期13-15,共3页
Journal of Clinical Medicine in Practice
基金
中国高校医学期刊临床专项资金(11220182)
